VIR – vir biotechnology, inc. (US:NASDAQ)
Stock Stats
News
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology [Yahoo! Finance]
Vir Biotechnology (NASDAQ:VIR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program [Yahoo! Finance]
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Form 8-K Vir Biotechnology, Inc. For: Dec 16
Form 4 Vir Biotechnology, Inc. For: Dec 01 Filed by: SVF Endurance (Cayman) Ltd
Form 4 Vir Biotechnology, Inc. For: Dec 01 Filed by: SATO VICKI L
Form 4 Vir Biotechnology, Inc. For: Nov 26 Filed by: SVF Endurance (Cayman) Ltd
Form 4 Vir Biotechnology, Inc. For: Nov 24 Filed by: SVF Endurance (Cayman) Ltd
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.